{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T23:10:59Z","timestamp":1791414659476,"version":"4.3.3"},"reference-count":53,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2010,10,1]],"date-time":"2010-10-01T00:00:00Z","timestamp":1285891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,10,1]],"date-time":"2010-10-01T00:00:00Z","timestamp":1285891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinical-colorectal-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Colorectal Cancer"],"published-print":{"date-parts":[[2010,10]]},"DOI":"10.3816\/ccc.2010.n.033","type":"journal-article","created":{"date-parts":[[2010,10,4]],"date-time":"2010-10-04T21:01:04Z","timestamp":1286226064000},"page":"224-228","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":69,"title":["Routine Dihydropyrimidine Dehydrogenase Testing for Anticipating 5-Fluorouracil\u2013Related Severe Toxicities: Hype or Hope?"],"prefix":"10.3816","volume":"9","author":[{"given":"Joseph","family":"Ciccolini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Gross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laetitia","family":"Dahan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Lacarelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9dric","family":"Mercier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.3816\/CCC.2010.n.033_bib1","first-page":"288","article-title":"Profiling dihydropyrimidine dehydrogenase deficiency in patients with cancer undergoing 5-fluorouracil\/capecitabine therapy","volume":"6","author":"Mercier","year":"2006","journal-title":"Clin Colorectal Cancer"},{"key":"10.3816\/CCC.2010.n.033_bib2","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.bbaexp.2006.05.001","article-title":"The role of Sp1 and Sp3 in the constitutive DPYD gene expression","volume":"1759","author":"Zhang","year":"2006","journal-title":"Biochim Biophys Acta"},{"key":"10.3816\/CCC.2010.n.033_bib3","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1200\/JCO.1994.12.11.2248","article-title":"Population study of dihydropyrimidine dehydrogenase in cancer patients","volume":"12","author":"Etienne","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.3816\/CCC.2010.n.033_bib4","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.tips.2007.09.009","article-title":"Severe or lethal toxicities upon capecitabine intake: is DPYD genetic polymorphism the ideal culprit?","volume":"28","author":"Mercier","year":"2007","journal-title":"Trends Pharmacol Sci"},{"key":"10.3816\/CCC.2010.n.033_bib5","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1056\/NEJM198507253130407","article-title":"Familial pyrimidinemia and pyrimidinuria associated with severe fluorouracil toxicity","volume":"313","author":"Tuchman","year":"1985","journal-title":"N Engl J Med"},{"key":"10.3816\/CCC.2010.n.033_bib6","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1006\/geno.1998.5379","article-title":"Characterization of the human dihydropyrimidine dehydrogenase gene","volume":"51","author":"Wei","year":"1998","journal-title":"Genomics"},{"key":"10.3816\/CCC.2010.n.033_bib7","doi-asserted-by":"crossref","first-page":"23192","DOI":"10.1016\/S0021-9258(17)31638-1","article-title":"cDNA cloning and chromosome mapping of human dihydropyrimidine dehydrogenase, an enzyme associated with 5-fluorouracil toxicity and congenital thymine uraciluria","volume":"269","author":"Yokota","year":"1994","journal-title":"J Biol Chem"},{"key":"10.3816\/CCC.2010.n.033_bib8","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1016\/S0959-8049(97)00261-X","article-title":"Heterozygosity for a point mutation in an invariant splice donor site ofd ihydropyrimidine dehydrogenase and severe 5-fluorouracil related toxicity","volume":"33","author":"Van Kuilenburg","year":"1997","journal-title":"Eur J Cancer"},{"key":"10.3816\/CCC.2010.n.033_bib9","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1046\/j.1365-2125.1998.00751.x","article-title":"Dihydropyrimidine dehydrogenase pharmacogenetics in Caucasian subjects","volume":"46","author":"Ridge","year":"1998","journal-title":"Br J Clin Pharmacol"},{"key":"10.3816\/CCC.2010.n.033_bib10","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1097\/00008571-200210000-00007","article-title":"High prevalence of the IVS14+1G > A mutation in the dihydropyrimidine dehydrogenase gene of patients with severe 5-fluorouracil-associated toxicity","volume":"12","author":"Van Kuilenburg","year":"2002","journal-title":"Pharmacogenetics"},{"key":"10.3816\/CCC.2010.n.033_bib11","first-page":"1149","article-title":"Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil: frequency of the common IVS14+1G>A mutation causing DPD deficiency","volume":"7","author":"Van Kuilenburg","year":"2001","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CCC.2010.n.033_bib12","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.clinbiochem.2009.09.024","article-title":"Two cases of 5-fluorouracil toxicity linked with gene variants in the DPYD gene","volume":"43","author":"Ofverholm","year":"2009","journal-title":"Clin Biochem"},{"key":"10.3816\/CCC.2010.n.033_bib13","doi-asserted-by":"crossref","first-page":"931","DOI":"10.2217\/pgs.09.28","article-title":"Dihydropyrimidine dehydrogenase gene variation and severe 5-fluorouracil toxicity: a haplotype assessment","volume":"10","author":"Amstutz","year":"2009","journal-title":"Pharmacogenomics"},{"key":"10.3816\/CCC.2010.n.033_bib14","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1006\/abio.2002.5666","article-title":"A high-throughput denaturing high-performance liquid chromatography method for the identification of variant alleles associated with dihydropyrimidine dehydrogenase deficiency","volume":"306","author":"Ezzeldin","year":"2002","journal-title":"Anal Biochem"},{"key":"10.3816\/CCC.2010.n.033_bib15","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/BF03256229","article-title":"Rapid detection of the DPYD IVS14+1G>A mutation for screening patients to prevent fluorouracil-related toxicity","volume":"11","author":"Bosch","year":"2007","journal-title":"Mol Diagn Ther"},{"key":"10.3816\/CCC.2010.n.033_bib16","doi-asserted-by":"crossref","first-page":"5886","DOI":"10.1158\/1078-0432.CCR-04-1784","article-title":"Analysis of the DPYD gene implicated in 5-fluorouracil catabolism in a cohort of Caucasian individuals","volume":"11","author":"Seck","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CCC.2010.n.033_bib17","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1200\/JCO.2006.10.4182","article-title":"Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group","volume":"26","author":"Schwab","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.3816\/CCC.2010.n.033_bib18","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1158\/1535-7163.MCT-06-0327","article-title":"Clinical relevance of different dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms on 5-fluorouracil tolerance","volume":"5","author":"Morel","year":"2006","journal-title":"Mol Cancer Ther"},{"key":"10.3816\/CCC.2010.n.033_bib19","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/BF02698048","article-title":"DPYD*5 gene mutation contributes to the reduced DPYD enzyme activity and chemotherapeutic toxicity of 5-FU: results from genotyping study on 75 gastric carcinoma and colon carcinoma patients","volume":"24","author":"Zhang","year":"2007","journal-title":"Med Oncol"},{"key":"10.3816\/CCC.2010.n.033_bib20","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/00008571-200004000-00002","article-title":"Known variant DPYD alleles do not explain DPD deficiency in cancer patients","volume":"10","author":"Collie-Duguid","year":"2000","journal-title":"Pharmacogenetics"},{"key":"10.3816\/CCC.2010.n.033_bib21","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s00280-009-1147-x","article-title":"The contribution of deleterious DPYD gene sequence variants to fluoropyrimidine toxicity in British cancer patients","volume":"65","author":"Loganayagam","year":"2009","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.3816\/CCC.2010.n.033_bib22","doi-asserted-by":"crossref","first-page":"e4003","DOI":"10.1371\/journal.pone.0004003","article-title":"Strong association of a common dihydropyrimidine dehydrogenase gene polymorphism with fluoropyrimidine-related toxicity in cancer patients","volume":"3","author":"Gross","year":"2008","journal-title":"PLoS ONE"},{"key":"10.3816\/CCC.2010.n.033_bib23","doi-asserted-by":"crossref","first-page":"303","DOI":"10.4149\/neo_2009_04_303","article-title":"Influence of dihydropyrimidine dehydrogenase gene (DPYD) coding sequence variants on the development of fluoropyrimidine-related toxicity in patients with high-grade toxicity and patients with excellent tolerance of fluoropyrimidine-based chemotherapy","volume":"56","author":"Kleibl","year":"2009","journal-title":"Neoplasma"},{"key":"10.3816\/CCC.2010.n.033_bib24","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1200\/JCO.2007.15.5481","article-title":"Predicting fluorouracil toxicity: can we finally do it?","volume":"26","author":"Ezzeldin","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.3816\/CCC.2010.n.033_bib25","doi-asserted-by":"crossref","first-page":"8699","DOI":"10.1158\/1078-0432.CCR-05-1520","article-title":"Methylation of the DPYD promoter: an alternative mechanism for dihydropyrimidine dehydrogenase deficiency in cancer patients","volume":"11","author":"Ezzeldin","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CCC.2010.n.033_bib26","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/1756-9966-27-54","article-title":"Hypermethylation of the DPYD promoter region is not a major predictor of severe toxicity in 5-fluorouracil based chemotherapy","volume":"27","author":"Amstutz","year":"2008","journal-title":"J Exp Clin Cancer Res"},{"key":"10.3816\/CCC.2010.n.033_bib27","first-page":"231","article-title":"Toxicity and efficacy of 5-fluorouracil and capecitabine in a patient with TYMS gene polymorphism: A challenge or a dilemma?","volume":"8","author":"Shahrokni","year":"2009","journal-title":"Clin Colorectal Cancer"},{"key":"10.3816\/CCC.2010.n.033_bib28","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/s00280-009-1071-0","article-title":"Contribution of dihydropyrimidinase gene alterations to the development of serious toxicity in fluoropyrimidine-treated cancer patients","volume":"65","author":"Fidlerova","year":"2009","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.3816\/CCC.2010.n.033_bib29","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1097\/FPC.0b013e3282f01788","article-title":"Genetic regulation of dihydropyrimidinase and its possible implication in altered uracil catabolism","volume":"17","author":"Thomas","year":"2007","journal-title":"Pharmacogenet Genomics"},{"key":"10.3816\/CCC.2010.n.033_bib30","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/FPC.0b013e3282f2f134","article-title":"Genetic regulation of beta-ureidopropionase and its possible implication in altered uracil catabolism","volume":"18","author":"Thomas","year":"2008","journal-title":"Pharmacogenet Genomics"},{"key":"10.3816\/CCC.2010.n.033_bib31","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1097\/01.ftd.0000245771.82720.c7","article-title":"A rapid and inexpensive method for anticipating severe toxicity to fluorouracil and fluorouracil-based chemotherapy","volume":"28","author":"Ciccolini","year":"2006","journal-title":"Ther Drug Monit"},{"key":"10.3816\/CCC.2010.n.033_bib32","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1023\/A:1012294617392","article-title":"Relationship between 5-fluorouracil disposition, toxicity and dihydropyrimidine dehydrogenase activity in cancer patients","volume":"12","author":"Di Paolo","year":"2001","journal-title":"Ann Oncol"},{"key":"10.3816\/CCC.2010.n.033_bib33","first-page":"2899","article-title":"Correlation between dihydropyrimidine dehydrogenase activity in peripheral mononuclear cells and systemic clearance of fluorouracil in cancer patients","volume":"52","author":"Fleming","year":"1992","journal-title":"Cancer Res"},{"key":"10.3816\/CCC.2010.n.033_bib34","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.clpt.2006.06.007","article-title":"A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity","volume":"80","author":"Bocci","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"10.3816\/CCC.2010.n.033_bib35","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/sj.tpj.6500476","article-title":"The influence of fluorouracil outcome parameters on tolerance and efficacy in patients with advanced colorectal cancer","volume":"8","author":"Capitain","year":"2008","journal-title":"Pharmacogenomics J"},{"issue":"18 suppl","key":"10.3816\/CCC.2010.n.033_bib36","first-page":"107s","article-title":"Prospective phenotypic screening for DPD deficiency in patients upon fluoropyrimidines administration: Impact on the reduction of drug-induced toxicities","volume":"25","author":"Mercier","year":"2007","journal-title":"J Clin Oncol"},{"issue":"15 suppl","key":"10.3816\/CCC.2010.n.033_bib37","first-page":"326s","article-title":"Pharmacoeconomic study in head and neck cancer patients: Impact of prospective DPD deficiency screening with 5-fluorouracil (5-FU) dose tailoring on toxicities-related costs","volume":"27","author":"Mercier","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.3816\/CCC.2010.n.033_bib38","article-title":"DPD-based adaptive dosing of 5-FU in patients with head and neck cancer: impact on treatment efficacy and toxicity","author":"Yang","year":"2010","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.3816\/CCC.2010.n.033_bib39","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/j.1365-2125.2008.03307.x","article-title":"Pharmacokinetics, a main actor in a many-sided approach to severe 5-FU toxicity prediction","volume":"67","author":"Bocci","year":"2009","journal-title":"Br J Clin Pharmacol"},{"key":"10.3816\/CCC.2010.n.033_bib40","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1007\/s10038-007-0186-6","article-title":"Genetic variations and haplotype structures of the DPYD gene encoding dihydropyrimidine dehydrogenase in Japanese and their ethnic differences","volume":"52","author":"Maekawa","year":"2007","journal-title":"J Hum Genet"},{"key":"10.3816\/CCC.2010.n.033_bib41","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s004390050637","article-title":"Dihydropyrimidine dehydrogenase (DPD) deficiency: identification and expression of missense mutations C29R, R886H and R235W","volume":"101","author":"Vreken","year":"1997","journal-title":"Hum Genet"},{"key":"10.3816\/CCC.2010.n.033_bib42","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1093\/annonc\/mdg056","article-title":"Lethal 5-fluorouracil toxicity associated with a novel mutation in the dihydropyrimidine dehydrogenase gene","volume":"14","author":"van Kuilenburg","year":"2003","journal-title":"Ann Oncol"},{"key":"10.3816\/CCC.2010.n.033_bib43","first-page":"2999","article-title":"Identification of novel mutations in the dihydropyrimidine dehydrogenase gene in a Japanese patient with 5-fluorouracil toxicity","volume":"4","author":"Kouwaki","year":"1998","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CCC.2010.n.033_bib44","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/j.1349-7006.2001.tb01100.x","article-title":"Germline mutation of dihydropyrimidine dehydrogenese gene among a Japanese population in relation to toxicity to 5-fluorouracil","volume":"92","author":"Yamaguchi","year":"2001","journal-title":"Jpn J Cancer Res"},{"key":"10.3816\/CCC.2010.n.033_bib45","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1042\/bj3640157","article-title":"Novel disease-causing mutations in the dihydropyrimidine dehydrogenase gene interpreted by analysis of the three-dimensional protein structure","volume":"364","author":"Van Kuilenburg","year":"2002","journal-title":"Biochem J"},{"key":"10.3816\/CCC.2010.n.033_bib46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/PL00008711","article-title":"Genotype and phenotype in patients with dihydropyrimidine dehydrogenase deficiency","volume":"104","author":"Van Kuilenburg","year":"1999","journal-title":"Hum Genet"},{"key":"10.3816\/CCC.2010.n.033_bib47","first-page":"768","article-title":"Profound dihydropyrimidine dehydrogenase deficiency resulting from a novel compound heterozygote genotype","volume":"8","author":"Johnson","year":"2002","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CCC.2010.n.033_bib48","first-page":"3021","article-title":"Denaturing high performance liquid chromatography analysis oft he DPYD gene in patients with lethal 5-fluorouracil toxicity","volume":"9","author":"Ezzeldin","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CCC.2010.n.033_bib49","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1515\/BC.2005.038","article-title":"Identification of three novel mutations in the dihydropyrimidine dehydrogenase gene associated with altered pre-mRNA splicing or protein function","volume":"386","author":"Van Kuilenburg","year":"2005","journal-title":"Biol Chem"},{"key":"10.3816\/CCC.2010.n.033_bib50","doi-asserted-by":"crossref","first-page":"5104","DOI":"10.1158\/1078-0432.CCR-05-0217","article-title":"Dihydropyrimidine dehydrogenase activity in 150 healthy Japanese volunteers and identification of novel mutations","volume":"11","author":"Ogura","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CCC.2010.n.033_bib51","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/j.1365-2710.2008.00898.x","article-title":"Analysis of the DPYD gene implicated in 5-fluorouracil catabolism in Chinese cancer patients","volume":"33","author":"He","year":"2008","journal-title":"J Clin Pharm Ther"},{"key":"10.3816\/CCC.2010.n.033_bib52","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1093\/jnci\/djp328","article-title":"Pharmacokinetically guided dose adjustment of 5-fluorouracil: a rational approach to improving therapeutic outcomes","volume":"101","author":"Saif","year":"2009","journal-title":"J Natl Cancer Inst"},{"key":"10.3816\/CCC.2010.n.033_bib53","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1097\/FTD.0b013e3181b9b8c0","article-title":"Multicenter evaluation of a novel nanoparticle immunoassay for 5-fluorouracil on the Olympus AU400 analyzer","volume":"31","author":"Beumer","year":"2009","journal-title":"Ther Drug Monit"}],"container-title":["Clinical Colorectal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1533002811700068?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1533002811700068?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T22:56:41Z","timestamp":1761519401000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1533002811700068"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10]]},"references-count":53,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,10]]}},"alternative-id":["S1533002811700068"],"URL":"https:\/\/doi.org\/10.3816\/ccc.2010.n.033","relation":{},"ISSN":["1533-0028"],"issn-type":[{"value":"1533-0028","type":"print"}],"subject":[],"published":{"date-parts":[[2010,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Routine Dihydropyrimidine Dehydrogenase Testing for Anticipating 5-Fluorouracil\u2013Related Severe Toxicities: Hype or Hope?","name":"articletitle","label":"Article Title"},{"value":"Clinical Colorectal Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.3816\/CCC.2010.n.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}